Nicole Negar  Davarpanah net worth and biography

Nicole Davarpanah Biography and Net Worth

Dr. Davarpanah joins the Cidara team with over 10 years of experience in immuno-oncology drug development and early and late-stage clinical trial design. Prior to joining the company, she served as a Clinical and Translational Lead in Oncology at Genentech/Roche, leading the development strategy of immunotherapy combinations in bladder cancer. Prior to that role, she was the Senior Medical Director of Genitourinary (GU) Immuno-Oncology and Medical Affairs at Genentech/Roche, where she was responsible for the launch of GU oncology products, as well as cultivating strategic partnerships with disease area experts, academic institutions, regulatory agencies and professional societies.

Dr. Davarpanah is a medical oncologist and clinician who has broad experience working in multiple health care systems including academic medicine, government, and private practice. Earlier in her career, she served as a research fellow focusing on immuno-oncology and GU Cancers at the National Cancer Institute (NCI/NIH) and as a faculty member at Georgetown University School of Medicine, lecturing on the intersection of medicine, law, and technology, and serving as a national speaker and advisor to medical centers and corporations to expand health care access to life saving treatments. Dr. Davarpanah received her Doctor of Medicine degree from Boston University and her Juris Doctor degree from the University of California, Berkeley.

What is Nicole Negar Davarpanah's net worth?

The estimated net worth of Nicole Negar Davarpanah is at least $6.93 million as of September 11th, 2025. Davarpanah owns 31,418 shares of Cidara Therapeutics stock worth more than $6,927,669 as of December 4th. This net worth evaluation does not reflect any other investments that Davarpanah may own. Learn More about Nicole Negar Davarpanah's net worth.

How do I contact Nicole Negar Davarpanah?

The corporate mailing address for Davarpanah and other Cidara Therapeutics executives is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. Cidara Therapeutics can also be reached via phone at (858) 752-6170 and via email at [email protected]. Learn More on Nicole Negar Davarpanah's contact information.

Has Nicole Negar Davarpanah been buying or selling shares of Cidara Therapeutics?

Nicole Negar Davarpanah has not been actively trading shares of Cidara Therapeutics within the last three months. Most recently, Nicole Negar Davarpanah sold 474 shares of the business's stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $62.86, for a transaction totalling $29,795.64. Following the completion of the sale, the insider now directly owns 31,418 shares of the company's stock, valued at $1,974,935.48. Learn More on Nicole Negar Davarpanah's trading history.

Who are Cidara Therapeutics' active insiders?

Cidara Therapeutics' insider roster includes Neil Abdollahian (Insider), Paul Daruwala (COO), Nicole Davarpanah (Insider), Timothy Franson (Director), Brady Johnson (VP), Jessica Oien (General Counsel), Preetam Shah (CFO), Jeffrey Stein (CEO), Leslie Tari (Insider), and Shane Ward (COO). Learn More on Cidara Therapeutics' active insiders.

Are insiders buying or selling shares of Cidara Therapeutics?

In the last twelve months, Cidara Therapeutics insiders bought shares 1 times. They purchased a total of 2,272,727 shares worth more than $99,999,988.00. In the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 3,911 shares worth more than $105,272.16. The most recent insider tranaction occured on September, 11th when insider Nicole Negar Davarpanah sold 474 shares worth more than $29,795.64. Insiders at Cidara Therapeutics own 3.9% of the company. Learn More about insider trades at Cidara Therapeutics.

Information on this page was last updated on 9/11/2025.

Nicole Negar Davarpanah Insider Trading History at Cidara Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/11/2025Sell474$62.86$29,795.6431,418View SEC Filing Icon  
See Full Table

Nicole Negar Davarpanah Buying and Selling Activity at Cidara Therapeutics

This chart shows Nicole Negar Davarpanah's buying and selling at Cidara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cidara Therapeutics Company Overview

Cidara Therapeutics logo
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Read More

Today's Range

Now: $220.50
Low: $219.86
High: $220.69

50 Day Range

MA: $137.53
Low: $90.50
High: $220.74

2 Week Range

Now: $220.50
Low: $15.22
High: $221.20

Volume

453,521 shs

Average Volume

2,245,477 shs

Market Capitalization

$6.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46